CN114732942A - Chlorine dioxide slow-release liquid band-aid and preparation method thereof - Google Patents
Chlorine dioxide slow-release liquid band-aid and preparation method thereof Download PDFInfo
- Publication number
- CN114732942A CN114732942A CN202210383861.7A CN202210383861A CN114732942A CN 114732942 A CN114732942 A CN 114732942A CN 202210383861 A CN202210383861 A CN 202210383861A CN 114732942 A CN114732942 A CN 114732942A
- Authority
- CN
- China
- Prior art keywords
- parts
- chlorine dioxide
- aid
- liquid band
- vinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 102
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 51
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 51
- 239000007788 liquid Substances 0.000 claims abstract description 42
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000013268 sustained release Methods 0.000 claims abstract description 31
- 239000012730 sustained-release form Substances 0.000 claims abstract description 31
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000017 hydrogel Substances 0.000 claims abstract description 27
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 21
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims abstract description 16
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940072049 amyl acetate Drugs 0.000 claims abstract description 11
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004359 castor oil Substances 0.000 claims abstract description 11
- 235000019438 castor oil Nutrition 0.000 claims abstract description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 11
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims abstract description 11
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims abstract description 11
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 8
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000003756 stirring Methods 0.000 claims description 15
- 230000008961 swelling Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 239000003999 initiator Substances 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000001102 lavandula vera Substances 0.000 claims description 2
- 235000018219 lavender Nutrition 0.000 claims description 2
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical group [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 34
- 208000027418 Wounds and injury Diseases 0.000 abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 230000029663 wound healing Effects 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 229940124350 antibacterial drug Drugs 0.000 abstract description 3
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 239000003640 drug residue Substances 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910001902 chlorine oxide Inorganic materials 0.000 description 1
- MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Chemical compound ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- -1 ethyl tocopherol Chemical compound 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012802 pre-warming Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/106—Halogens or compounds thereof, e.g. iodine, chlorite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种二氧化氯缓释型液体创可贴及其制备方法,该创可贴包括以下重量份的组分:丙烯酸/N‑乙烯基吡咯烷酮水凝胶20‑30份、异丙醇24‑36份、乙酸丁酯8‑12份、乙酸戊酯8‑12份、蓖麻油2‑5份、生育酚乙酸酯0.2‑3份、苯甲醇2‑8份、二氧化氯5‑20份、医药级氮酮3‑5份。该创可贴有着良好的抗菌性能,对多种病原菌的生长有明显的抑制活性,并兼具防水、透气性能,所选成膜材料可以实现二氧化氯在伤口表面的缓释,延长作用效应,减少给药次数并能减少药物残留,避免伤口细菌产生耐药性,有效促进伤口愈合,可有效解决现有的创口贴存在的抑菌效果差、抑菌药物量大导致伤口表面细菌产生耐药性的问题。The invention provides a chlorine dioxide sustained-release liquid Band-Aid and a preparation method thereof. The Band-Aid comprises the following components in parts by weight: 20-30 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 24-36 parts of isopropanol parts, 8-12 parts of butyl acetate, 8-12 parts of amyl acetate, 2-5 parts of castor oil, 0.2-3 parts of tocopheryl acetate, 2-8 parts of benzyl alcohol, 5-20 parts of chlorine dioxide, 3-5 parts of pharmaceutical grade azone. The band-aid has good antibacterial properties, has obvious inhibitory activity against the growth of various pathogenic bacteria, and has both waterproof and breathable properties. The selected film-forming material can realize the sustained release of chlorine dioxide on the wound surface, prolong the effect and reduce the The number of administrations can also reduce drug residues, prevent wound bacteria from developing drug resistance, effectively promote wound healing, and can effectively solve the problem of poor bacteriostatic effect and large amount of antibacterial drugs in existing wound dressings, resulting in drug resistance of wound surface bacteria. The problem.
Description
技术领域technical field
本发明属于创可贴技术领域,具体涉及一种二氧化氯缓释型液体创可贴及其制备方法。The invention belongs to the technical field of band-aids, and in particular relates to a chlorine dioxide sustained-release liquid band-aid and a preparation method thereof.
背景技术Background technique
日常生活中,皮肤轻微的擦伤、刮伤、割伤等伤口极为常见,对于此类伤口,人们普遍采用传统创可贴进行简单贴敷,然而传统创口贴不足之处有:可引起少数人出现皮肤过敏反应;粘连伤口,更换时导致机械性再损伤;吸收能力有限;不能防水,细菌易穿透易感染,结痂阻碍了伤口的愈合;涂抹部位因为胶布包扎而发白;大小面积覆盖和活动部位受限等。为解决以上问题,目前市面上已有液体创可贴产品出现,液体创可贴是将成膜材料溶解在溶剂中制成的瓶装药剂,可以通过喷洒或涂抹的方式紧紧黏附于皮肤表面,即使直接与水接触也不会发生渗透,可以对伤口起到很好的保护作用。In daily life, minor skin abrasions, scratches, cuts and other wounds are very common. For such wounds, people generally use traditional band-aids for simple application. However, the shortcomings of traditional band-aids are: it can cause skin to appear in a few people. Allergic reaction; adhesion of the wound, resulting in mechanical re-injury during replacement; limited absorption capacity; not waterproof, easily penetrated by bacteria and susceptible to infection, and scabs hinder the healing of the wound; the application site is white due to the tape bandage; large and small area coverage and movement Site restrictions, etc. In order to solve the above problems, there are currently liquid Band-Aid products on the market. Liquid Band-Aid is a bottled medicine made by dissolving film-forming materials in a solvent. It can be tightly adhered to the skin surface by spraying or smearing. Contact will not occur penetration, can play a good role in wound protection.
然而,目前的液体创可贴仍有不足之处,例如:作为伤口敷料,产品中的抑菌物质采用的是8-羟基喹啉、苯扎氯铵、多西环素等材料,此类抑菌材料会对人体产生毒副作用、引起过敏反应;产品中加入的抑菌剂量大但有效作用时间短。伤口表面抑菌药物过量,久而久之就会导致伤口表面细菌产生耐药性,这尤其非常不利于糖尿病足、褥疮等慢性伤口的愈合,甚至可能因为细菌耐药性加重病情。此外,产品的止血性能较差。However, the current liquid Band-Aid still has shortcomings. For example, as a wound dressing, the antibacterial substances in the product are 8-hydroxyquinoline, benzalkonium chloride, doxycycline and other materials. Such antibacterial materials It will have toxic and side effects on the human body and cause allergic reactions; the antibacterial dose added to the product is large but the effective time is short. Excessive antibacterial drugs on the wound surface will lead to drug resistance of bacteria on the wound surface over time, which is particularly unfavorable for the healing of chronic wounds such as diabetic foot and bedsores, and may even aggravate the disease due to bacterial resistance. In addition, the hemostatic properties of the product are poor.
二氧化氯是一种安全、高效、广谱、强力杀菌剂,是联合国世界卫生组织 (WHO)公认的A1级消毒剂。二氧化氯有效氯是氯气的2.63倍,杀菌能力是氯气的5倍,是次氯酸钠的45倍以上。国内外大量研究表明:低剂量使用二氧化氯对高等动植物无致癌、致畸、致突变作用。但是,现有技术中使用的二氧化氯剂量普遍偏大,易造成皮肤湿疹、皮损等问题,进而导致更严重的问题。Chlorine dioxide is a safe, efficient, broad-spectrum, and powerful disinfectant, and is recognized by the United Nations World Health Organization (WHO) as an A1-level disinfectant. The effective chlorine of chlorine dioxide is 2.63 times that of chlorine gas, the sterilization ability is 5 times that of chlorine gas, and more than 45 times that of sodium hypochlorite. A large number of studies at home and abroad have shown that: the use of low-dose chlorine dioxide has no carcinogenic, teratogenic and mutagenic effects on higher animals and plants. However, the dosage of chlorine dioxide used in the prior art is generally too large, which is likely to cause problems such as skin eczema and skin lesions, which in turn leads to more serious problems.
发明内容SUMMARY OF THE INVENTION
针对现有技术中存在的上述问题,本发明提供一种二氧化氯缓释型液体创可贴及其制备方法,该创可贴有着良好的抗菌性能,对多种病原菌的生长有明显的抑制活性,并兼具防水、透气性能,所选成膜材料可以实现二氧化氯在伤口表面的缓释,延长作用效应,减少给药次数并能减少药物残留,避免伤口细菌产生耐药性,有效促进伤口愈合,可有效解决现有的创口贴存在的抑菌效果差、抑菌药物量大导致伤口表面细菌产生耐药性的问题。In view of the above problems existing in the prior art, the present invention provides a chlorine dioxide sustained-release liquid band-aid and a preparation method thereof. The band-aid has good antibacterial properties, has obvious inhibitory activity against the growth of various pathogenic bacteria, and has both With waterproof and breathable properties, the selected film-forming material can realize the slow release of chlorine dioxide on the wound surface, prolong the effect, reduce the number of administrations and reduce drug residues, avoid the resistance of wound bacteria, and effectively promote wound healing. The invention can effectively solve the problems of poor antibacterial effect and large amount of antibacterial drugs in the existing wound sticks, which lead to drug resistance of bacteria on the wound surface.
为实现上述目的,本发明解决其技术问题所采用的技术方案是:For realizing the above-mentioned purpose, the technical scheme that the present invention solves its technical problem adopts is:
一种二氧化氯缓释型液体创可贴,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶20-30份、异丙醇24-36份、乙酸丁酯8-12份、乙酸戊酯8-12 份、蓖麻油2-5份、生育酚乙酸酯0.2-3份、苯甲醇2-8份、二氧化氯5-20份、医药级氮酮3-5份。A chlorine dioxide sustained-release liquid Band-Aid, comprising the following components by weight: 20-30 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 24-36 parts of isopropanol, 8-12 parts of butyl acetate, 8-12 parts of amyl acetate, 2-5 parts of castor oil, 0.2-3 parts of tocopheryl acetate, 2-8 parts of benzyl alcohol, 5-20 parts of chlorine dioxide, and 3-5 parts of pharmaceutical grade azone.
进一步地,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶30 份、异丙醇30份、乙酸丁酯8份、乙酸戊酯8份、蓖麻油5份、生育酚乙酸酯 1份、苯甲醇5份、二氧化氯15份、医药级氮酮3份。Further, the following components are included in parts by weight: 30 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 30 parts of isopropanol, 8 parts of butyl acetate, 8 parts of amyl acetate, 5 parts of castor oil,
进一步地,丙烯酸/N-乙烯基吡咯烷酮水凝胶采用如下方法制得:将N-乙烯基吡咯烷酮溶解于蒸馏水中,保持0.5h,边搅拌边加入丙烯酸单体并加入交联剂和引发剂,然后于55-65℃密封水浴环境中反应20-30h,取出产物,用蒸馏水反复浸泡洗涤,充分纯化,制得。Further, the acrylic acid/N-vinylpyrrolidone hydrogel is prepared by the following method: dissolving the N-vinylpyrrolidone in distilled water, keeping for 0.5h, adding acrylic monomer and adding a crosslinking agent and an initiator while stirring, Then react in a sealed water bath environment at 55-65°C for 20-30 hours, take out the product, soak and wash repeatedly with distilled water, fully purify and prepare.
进一步地,N-乙烯基吡咯烷酮与丙烯酸单体的质量比为3:1,交联剂的用量为N-乙烯基吡咯烷酮单体质量的1.5wt%,引发剂的用量为N-乙烯基吡咯烷酮单体质量的0.8wt%。Further, the mass ratio of N-vinylpyrrolidone to acrylic monomer is 3:1, the amount of crosslinking agent is 1.5 wt% of the mass of N-vinylpyrrolidone monomer, and the amount of initiator is N-vinylpyrrolidone monomer. 0.8 wt% of body mass.
进一步地,交联剂为N-N’亚甲基双丙烯酰胺,所述引发剂为过硫酸钾、过硫酸铵或偶氮二异丁腈。Further, the crosslinking agent is N-N' methylenebisacrylamide, and the initiator is potassium persulfate, ammonium persulfate or azobisisobutyronitrile.
进一步地,还包括赋香精油0.5-2份。Further, 0.5-2 parts of fragrance essential oil are also included.
进一步地,赋香精油为薰衣草精油或薄荷精油。Further, the fragrance essential oil is lavender essential oil or peppermint essential oil.
上述的二氧化氯缓释型液体创可贴的制备方法,包括以下步骤:将异丙酮和乙酸丁酯混合,在搅拌条件下向其中加入丙烯酸/N-乙烯基吡咯烷酮水凝胶,然后升温至溶胀,再向其中加入剩余原料,于避光保温条件下搅拌反应,制得。The preparation method of the above-mentioned chlorine dioxide sustained-release liquid Band-Aid, comprising the following steps: mixing isoacetone and butyl acetate, adding acrylic acid/N-vinylpyrrolidone hydrogel to it under stirring conditions, then warming up to swelling, The remaining raw materials are added to it, and the reaction is stirred and reacted under the condition of keeping away from light and heat to obtain the product.
进一步地,升温至40-60℃后至充分溶胀,加入剩余原料,然后于40-60℃避光条件下300r/min--500r/min的转速下搅拌反应。Further, the temperature is raised to 40-60°C until fully swollen, the remaining raw materials are added, and then the reaction is stirred at a rotational speed of 300r/min--500r/min under the dark condition of 40-60°C.
进一步地,于避光条件下搅拌反应时间为2-4h。Further, the stirring reaction time is 2-4h under the dark condition.
本发明所产生的有益效果为:The beneficial effects produced by the present invention are:
本申请中选用丙烯酸/N-乙烯基吡咯烷酮水凝胶对二氧化氯分子进行包裹,可以实现二氧化氯在伤口表面的缓释作用,延长药物作用时间,减少给药次数,具体为:丙烯酸/N-乙烯基吡咯烷酮水凝胶内部存在互穿的网络结构,其为PH 响应型水凝胶,水凝胶立体网状结构中含有大量不能移动的羧基,在不同PH值时,羧基解离程度不同,互穿网络中静电排斥作用不同,在伤口表面未发生感染时,PH值为5-7,此时羧基-COOH之间氢键缔合,水凝胶溶胀率低,药物二氧化氯释放量少,可预防伤口表面发炎。当伤口出现炎症,伤口表面呈碱性,此时羧基-COOH逐渐解离为-COO-,凝胶网络中氢键解离,离子之间静电排斥作用显著增大,溶胀率增大,包藏在凝胶网络中的二氧化氯分子大量释放,从而解决伤口表面发炎情况。由此可知本发明中的高分子材料通过网络互穿缠结,可以实现PH值响应。In this application, acrylic acid/N-vinylpyrrolidone hydrogel is used to encapsulate chlorine dioxide molecules, which can realize the sustained release effect of chlorine dioxide on the wound surface, prolong the action time of the drug, and reduce the number of administrations, specifically: acrylic acid/N-vinylpyrrolidone hydrogel There is an interpenetrating network structure inside the N-vinylpyrrolidone hydrogel, which is a pH-responsive hydrogel. The three-dimensional network structure of the hydrogel contains a large number of immobile carboxyl groups. At different pH values, the degree of dissociation of carboxyl groups Different, the electrostatic repulsion in the interpenetrating network is different. When there is no infection on the wound surface, the pH value is 5-7. At this time, the hydrogen bond between the carboxyl group and COOH is associated, the hydrogel swelling rate is low, and the drug chlorine dioxide is released. A small amount can prevent inflammation of the wound surface. When the wound is inflamed and the surface of the wound is alkaline, the carboxyl-COOH gradually dissociates into -COO-, the hydrogen bonds in the gel network dissociate, the electrostatic repulsion between ions increases significantly, and the swelling rate increases. Chlorine dioxide molecules in the gel network are released in large quantities, thereby resolving the inflammation on the wound surface. It can be seen that the polymer material in the present invention can achieve pH value response through network interpenetration and entanglement.
该液体创口贴具有较强的抑菌能力,抑菌试验表明该产品在2min内对金黄葡萄球菌、绿脓杆菌等进行有效杀灭,同时,二氧化氯也具有一定的止血能力,更有利于伤口的处理。The liquid wound patch has strong antibacterial ability. The antibacterial test shows that the product can effectively kill Staphylococcus aureus, Pseudomonas aeruginosa, etc. within 2 minutes. At the same time, chlorine dioxide also has a certain hemostatic ability, which is more conducive to Treatment of wounds.
该液体创口贴使用方便,只需对伤口进行简单清洁后,将产品涂抹于创伤部位,产品可迅速形成透明状的膜。所形成的弹性透明膜具有透气性好的创口保护作用,它还具有良好的防水性,即使直接与水接触浸泡也不会产生渗透,可以将创面的持续消毒功能与创面的持续保护功能合二为一。该透明状的膜方便观察伤口愈合情况,待伤口愈合后,可以将膜直接撕下。本产品还对液体创可贴的杀菌、止血、创口治愈等性能进行了改善。在保证使用效果的同时,对材料进行选择,从而将生产成本降到最低,大大降低了液体创可贴产品的价格。The liquid wound patch is easy to use, and after simple cleaning of the wound, the product is smeared on the wound site, and the product can quickly form a transparent film. The elastic transparent film formed has good air permeability and wound protection, and it also has good water resistance. Even if it is directly immersed in water, it will not cause penetration. It can combine the continuous disinfection function of the wound surface with the continuous protection function of the wound surface. for one. The transparent film is convenient to observe the wound healing, and after the wound heals, the film can be torn off directly. This product also improves the sterilization, hemostasis, wound healing and other properties of liquid band-aids. While ensuring the effect of use, the material is selected to minimize the production cost and greatly reduce the price of liquid Band-Aid products.
附图说明Description of drawings
图1为揭膜过程的照片;Fig. 1 is a photo of the peeling process;
图2为实施例2中创可贴的抑菌效果图;Fig. 2 is the bacteriostatic effect figure of Band-Aid in Example 2;
图3为实施例1-4和对比例1-2中液体创可贴的药物释放曲线图;Fig. 3 is the drug release curve diagram of liquid Band-Aid in Example 1-4 and Comparative Example 1-2;
图4为实施例2和对比例2的液体创可贴的溶胀率变化曲线。FIG. 4 is the change curve of the swelling rate of the liquid Band-Aid of Example 2 and Comparative Example 2. FIG.
具体实施方式Detailed ways
下面结合附图对本发明的具体实施方式做详细的说明。The specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings.
实施例1Example 1
一种二氧化氯缓释型液体创可贴,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶20份、异丙醇25份、乙酸丁酯10份、乙酸戊酯10份、蓖麻油4份、生育酚乙酸酯3份、苯甲醇6份、二氧化氯10份、医药级氮酮5份。A chlorine dioxide sustained-release liquid Band-Aid, comprising the following components by weight: 20 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 25 parts of isopropanol, 10 parts of butyl acetate, 10 parts of amyl acetate, 4 parts of castor oil, 3 parts of tocopherol acetate, 6 parts of benzyl alcohol, 10 parts of chlorine dioxide, 5 parts of pharmaceutical grade azone.
上述的二氧化氯缓释型液体创可贴的制备方法,包括以下步骤:The preparation method of above-mentioned chlorine dioxide sustained-release liquid Band-Aid, comprises the following steps:
将异丙酮和乙酸丁酯混合,在搅拌条件下向其中加入丙烯酸/N-乙烯基吡咯烷酮水凝胶,然后升温至50℃溶胀完全,再向其中加入剩余原料,于50℃避光保温条件下400r/min的转速下搅拌反应3h,制得。Mix isoacetone and butyl acetate, add acrylic acid/N-vinylpyrrolidone hydrogel to it under stirring condition, then heat up to 50°C to swell completely, then add the remaining raw materials to it, and keep it at 50°C under the condition of avoiding light and keeping warm. The product was prepared by stirring and reacting for 3h at a rotating speed of 400r/min.
实施例2Example 2
一种二氧化氯缓释型液体创可贴,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶30份、异丙醇30份、乙酸丁酯8份、乙酸戊酯8份、蓖麻油5份、生育酚乙酸酯1份、苯甲醇5份、二氧化氯15份、医药级氮酮3份。A chlorine dioxide sustained-release liquid Band-Aid, comprising the following components by weight: 30 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 30 parts of isopropanol, 8 parts of butyl acetate, 8 parts of amyl acetate, 5 parts of castor oil, 1 part of tocopherol acetate, 5 parts of benzyl alcohol, 15 parts of chlorine dioxide, 3 parts of pharmaceutical grade azone.
上述的二氧化氯缓释型液体创可贴的制备方法,包括以下步骤:The preparation method of above-mentioned chlorine dioxide sustained-release liquid Band-Aid, comprises the following steps:
将异丙酮和乙酸丁酯混合,在搅拌条件下向其中加入丙烯酸/N-乙烯基吡咯烷酮水凝胶,然后升温至60℃溶胀完全,再向其中加入剩余原料,于60℃避光保温条件下500r/min的转速下搅拌反应4h,制得。Mix isoacetone and butyl acetate, add acrylic acid/N-vinylpyrrolidone hydrogel to it under stirring, then heat up to 60°C to swell completely, then add the remaining raw materials to it, and keep it at 60°C in the dark and keep warm. It was prepared by stirring and reacting for 4h at a rotating speed of 500r/min.
实施例3Example 3
一种二氧化氯缓释型液体创可贴,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶25份、异丙醇24份、乙酸丁酯12份、乙酸戊酯12份、蓖麻油3份、生育酚乙酸酯2份、苯甲醇4份、二氧化氯15份、医药级氮酮5份。A chlorine dioxide sustained-release liquid Band-Aid, comprising the following components by weight: 25 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 24 parts of isopropanol, 12 parts of butyl acetate, 12 parts of amyl acetate, 3 parts of castor oil, 2 parts of tocopheryl acetate, 4 parts of benzyl alcohol, 15 parts of chlorine dioxide, 5 parts of pharmaceutical grade azone.
上述的二氧化氯缓释型液体创可贴的制备方法,包括以下步骤:The preparation method of above-mentioned chlorine dioxide sustained-release liquid Band-Aid, comprises the following steps:
将异丙酮和乙酸丁酯混合,在搅拌条件下向其中加入丙烯酸/N-乙烯基吡咯烷酮水凝胶,然后升温至40℃溶胀完全,再向其中加入剩余原料,于40℃避光保温条件下300r/min的转速下搅拌反应2h,制得。Mix isoacetone and butyl acetate, add acrylic acid/N-vinylpyrrolidone hydrogel to it under stirring condition, then heat up to 40°C to swell completely, then add the remaining raw materials to it, and keep it at 40°C under the condition of keeping away from light and keeping warm. The product was prepared by stirring and reacting for 2h at a rotational speed of 300r/min.
实施例4Example 4
一种二氧化氯缓释型液体创可贴,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶27份、异丙醇36份、乙酸丁酯12份、乙酸戊酯12份、蓖麻油3份、生育酚乙酸酯3份、苯甲醇2份、二氧化氯20份、医药级氮酮3份。A chlorine dioxide sustained-release liquid Band-Aid, comprising the following components by weight: 27 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 36 parts of isopropanol, 12 parts of butyl acetate, 12 parts of amyl acetate, 3 parts of castor oil, 3 parts of tocopheryl acetate, 2 parts of benzyl alcohol, 20 parts of chlorine dioxide, 3 parts of pharmaceutical grade azone.
上述的二氧化氯缓释型液体创可贴的制备方法,包括以下步骤:The preparation method of above-mentioned chlorine dioxide sustained-release liquid Band-Aid, comprises the following steps:
将异丙酮和乙酸丁酯混合,在搅拌条件下向其中加入丙烯酸/N-乙烯基吡咯烷酮水凝胶,然后升温至55℃溶胀完全,再向其中加入剩余原料,于55℃避光保温条件下450r/min的转速下搅拌反应2h,制得。Mix isoacetone and butyl acetate, add acrylic acid/N-vinylpyrrolidone hydrogel to it under stirring conditions, then heat up to 55°C to swell completely, then add the remaining raw materials to it, and keep it at 55°C under the condition of avoiding light and keeping warm. The product was prepared by stirring and reacting for 2h at a rotating speed of 450r/min.
对比例1Comparative Example 1
一种液体创可贴,包括以下重量份的组分:丙烯酸/N-乙烯基吡咯烷酮水凝胶30份、异丙醇30份、乙酸丁酯8份、乙酸戊酯8份、蓖麻油5份、生育酚乙酸酯1份、苯甲醇5份、医药级氮酮3份。A liquid Band-Aid, comprising the following components in parts by weight: 30 parts of acrylic acid/N-vinylpyrrolidone hydrogel, 30 parts of isopropanol, 8 parts of butyl acetate, 8 parts of amyl acetate, 5 parts of castor oil,
制备方法同实施例2。The preparation method is the same as that of Example 2.
对比例2Comparative Example 2
一种二氧化氯缓释型液体创可贴,包括以下重量份的组分:聚乙烯吡咯烷酮30份、异丙醇30份、乙酸丁酯8份、乙酸戊酯8份、蓖麻油5份、生育酚乙酸酯1份、苯甲醇5份、二氧化氯15份、医药级氮酮3份。A chlorine dioxide sustained-release liquid band-aid, comprising the following components by weight: 30 parts of polyvinylpyrrolidone, 30 parts of isopropanol, 8 parts of butyl acetate, 8 parts of amyl acetate, 5 parts of castor oil, and
制备方法同实施例2。The preparation method is the same as that of Example 2.
试验例Test example
分别对实施例1-4和对比例1-2中制得的液体创可贴进行性能检测,具体测试方法如下:The liquid band-aids prepared in Examples 1-4 and Comparative Examples 1-2 were respectively tested for performance, and the specific test method was as follows:
(1)成膜时间测定:(1) Determination of film forming time:
分别取实施例1-4制备而成的液体创可贴约0.5g倾倒在培养皿上,使其自然均匀的流布整个表面皿,厚度约为0.2mm,膜能揭起时,记录所用时间;揭膜过程如图1所示。Take about 0.5g of the liquid Band-Aid prepared in Examples 1-4 and pour it on the petri dish, so that it can be spread over the entire watch dish naturally and evenly, with a thickness of about 0.2mm. When the film can be lifted, record the time used; The process is shown in Figure 1.
(2)膜机械性能测试:(2) Membrane mechanical properties test:
分别取实施例1-4制备而成的液体创可贴约0.5g,倒入培养皿中,静置5 分钟,使之流延成膜,横切面积分别为30mm×(0.020mm±0.003mm)为膜的横截面积S(mm2)。轻轻地揭下薄膜,注意应使切出的膜边缘光滑无缺口,两端夹于拉伸试验仪中,此时位于两个夹子中间的薄膜的长度记为膜测试前的长度(L0)。以2.5mm/min的拉伸速度,500N的载荷量进行实验,当薄膜从中央断裂时,记下此时的断裂力量F(N)和两端夹子的距离Lmax(mm)。则抗张强度 Tensile=F/S,断点伸长百分率Elongation=Lmax/L0,测试结果见表1。Take about 0.5g of the liquid Band-Aid prepared in Examples 1-4, pour it into a petri dish, let it stand for 5 minutes, and make it cast into a film. The cross-sectional area is 30mm×(0.020mm±0.003mm) respectively. The cross-sectional area S (mm 2 ) of the membrane. Gently peel off the film, pay attention to make the edge of the cut film smooth without nicks, and clamp both ends in the tensile tester. At this time, the length of the film between the two clamps is recorded as the length before the film test (L 0 ). The experiment was carried out at a tensile speed of 2.5 mm/min and a load of 500 N. When the film was broken from the center, the breaking force F (N) and the distance L max (mm) of the clips at both ends were recorded. Then the tensile strength Tensile=F/S, the elongation percentage at break point Elongation=Lmax/L 0 , and the test results are shown in Table 1.
表1产品成膜时间及机械性能测试数据表Table 1 Product film forming time and mechanical properties test data table
(3)透气性测试:(3) Air permeability test:
以水蒸气透过率为评价标准,考察单位时间内通过单位薄膜面积的水蒸气质量。取样品约1g,流延成膜,在10mL西林瓶中加入适量蒸馏水,以薄膜覆盖密封,使水液面距薄膜5mm±2mm,置于干燥器中,24小时后记录重量差异。Using the water vapor transmission rate as the evaluation standard, the mass of water vapor passing through the unit film area per unit time was investigated. Take about 1 g of the sample, cast it into a film, add an appropriate amount of distilled water to a 10 mL vial, cover it with a film and seal it so that the water surface is 5mm±2mm away from the film, place it in a desiccator, and record the weight difference after 24 hours.
M0=初始西林瓶的重量(mg)M 0 = weight of initial vial (mg)
M24h=24h后西林瓶的质量(mg)M 24h = mass of vial after 24h (mg)
S=瓶口面积(mm2)S = bottle mouth area (mm 2 )
t=时间(h)t = time (h)
结果显示,实施例1中样品在24小时内水蒸气透过率可达0.7mg·cm-2·h;实施例2中样品在24小时内水蒸气透过率可达0.8mg·cm-2·h;实施例3中样品在24小时内水蒸气透过率可达0.8mg·cm-2·h;实施例4中样品在24小时内水蒸气透过率可达0.6mg·cm-2·h;对比例1样品24小时内水蒸气透过率为 0.7mg·cm-2·h;对比例2样品24小时内水蒸气透过率为0.6mg·cm-2·h。The results show that the water vapor transmission rate of the sample in Example 1 can reach 0.7 mg·cm -2 ·h within 24 hours; the water vapor transmission rate of the sample in Example 2 can reach 0.8 mg·cm -2 within 24 hours h; the water vapor transmission rate of the sample in Example 3 can reach 0.8 mg·cm -2 h within 24 hours; the water vapor transmission rate of the sample in Example 4 can reach 0.6 mg·cm -2 in 24 hours ·h; the water vapor transmission rate of the sample of Comparative Example 1 within 24 hours was 0.7 mg·cm -2 ·h; the water vapor transmission rate of the sample of Comparative Example 2 within 24 hours was 0.6 mg·cm -2 ·h.
(4)防水性测试:(4) Waterproof test:
分别取实施例1-4制备而成的液体创可贴约1.0g,流延成膜,取一口径为 12mm的西林瓶,其中加入5ml蒸馏水,以上述所成薄膜覆盖西林瓶,倒置,24 小时后记录质量差,计算水渗透率。Take about 1.0 g of the liquid Band-Aid prepared in Examples 1-4 respectively, cast to form a film, take a vial with a diameter of 12 mm, add 5 ml of distilled water, cover the vial with the above-mentioned film, invert, after 24 hours. Poor recording quality, water permeability was calculated.
M0=初始西林瓶的重量/gM 0 = weight of initial vial/g
M24h=24h后西林瓶的质量/gM 24h = mass/g of vial after 24h
Mw=西林瓶中水的质量/gM w = mass of water in vial/g
结果显示,实施例1中样品在24小时的水渗透率为1.8%;实施例2中样品在24小时的水渗透率为1.7%;实施例3中样品在24小时的水渗透率为1.9%;实施例4中样品在24小时的水渗透率为1.9%,对比例1样品在24小时的水渗透率为1.8%;对比例2样品在24小时的水渗透率为2.2%。The results show that the water permeability of the sample in Example 1 is 1.8% in 24 hours; the water permeability of the sample in Example 2 is 1.7% in 24 hours; the water permeability of the sample in Example 3 is 1.9% in 24 hours The water permeability of the sample in Example 4 is 1.9% at 24 hours, the water permeability of the sample of Comparative Example 1 at 24 hours is 1.8%; the water permeability of the sample of Comparative Example 2 at 24 hours is 2.2%.
(5)抗菌测试:(5) Antibacterial test:
由于实施例2成膜时间及机械性能在四种实施案例中效果最好,所以实施例2进行抑菌测试。以无菌接种环分别蘸取金黄色葡萄球菌、绿脓杆菌菌悬液,均匀涂布于培养基表面,取实施例2制备而成的液体创可贴产品10.0μL于上述培养基表面,于25℃恒温培养箱培养,并观察不同时间下产品抑菌效果,具体结果见图2。Since the film-forming time and mechanical properties of Example 2 are the best among the four implementation cases, the antibacterial test is carried out in Example 2. Dip the bacterial suspensions of Staphylococcus aureus and Pseudomonas aeruginosa respectively with a sterile inoculating loop, spread them evenly on the surface of the medium, and take 10.0 μL of the liquid Band-Aid product prepared in Example 2 on the surface of the above-mentioned medium, at 25° C. Culture in a constant temperature incubator, and observe the antibacterial effect of the product at different times. The specific results are shown in Figure 2.
通过图2可以看出,制备而成的二氧化氯缓释型液体创可贴有极强的杀菌作用,可在2min内对金黄色葡萄球菌、绿脓杆菌等进行有效杀灭,抗菌效果显著,可有效预防伤口感染。It can be seen from Figure 2 that the prepared chlorine dioxide sustained-release liquid band-aid has a strong bactericidal effect, and can effectively kill Staphylococcus aureus, Pseudomonas aeruginosa, etc. within 2 minutes, and has a significant antibacterial effect, which can Effectively prevent wound infection.
(6)缓释效果测试:(6) Slow release effect test:
按照中国药典要求,采用透皮吸收仪为药物体外释放度测试装置,将透析膜首先用1mmol/L EDTA和0.2mmol/L碳酸氢钠煮沸15min,蒸馏水清洗后模拟动物皮肤,以生理盐水作为接受介质,结合紫外分光光度法测定不同时间内药物中二氧化氯单位面积渗透量,以时间为横坐标,药物累积释放量为纵坐标,绘制二氧化氯缓释型液体创可贴的释放曲线。将得到的累积释放量-时间曲线数据进行Higuchi方程拟合及回归分析,判断二氧化氯缓释型液体创可贴的缓释效果,具体结果见图3和表2。According to the requirements of the Chinese Pharmacopoeia, a transdermal absorption device was used as the test device for drug release in vitro. The dialysis membrane was first boiled with 1 mmol/L EDTA and 0.2 mmol/L sodium bicarbonate for 15 minutes, washed with distilled water to simulate animal skin, and normal saline was used as the recipient. The medium, combined with UV spectrophotometry to determine the permeation amount of chlorine dioxide per unit area in the drug at different times, taking the time as the abscissa and the cumulative release of the drug as the ordinate, to draw the release curve of the chlorine dioxide sustained-release liquid Band-Aid. The obtained cumulative release-time curve data was subjected to Higuchi equation fitting and regression analysis to determine the sustained-release effect of the chlorine dioxide sustained-release liquid Band-Aid. The specific results are shown in Figure 3 and Table 2.
表2体外释放度Higuchi方程拟合数据表Table 2 Higuchi equation fitting data table for in vitro release
实施例1-4体外释放度曲线符合Higuchi方程,证明产品可以有效实现二氧化氯抑菌药物的缓释,释放过程先快后慢,既可以保证使用初期达到预防和治疗创面感染的药物浓度,又可以缓慢持久释放,延长作用效应,减少换药次数,加快伤口愈合。The in vitro release curve of Examples 1-4 conforms to the Higuchi equation, which proves that the product can effectively realize the sustained release of chlorine dioxide bacteriostatic drugs, and the release process is first fast and then slow, which can ensure that the drug concentration for preventing and treating wound infection in the initial stage of use can be achieved, It can also be released slowly and persistently, prolong the effect, reduce the number of dressing changes, and speed up wound healing.
(7)止血性能测试:(7) Hemostatic performance test:
取小鼠静脉血20.0ml,加入放有2.0ml 3.5%柠檬酸钠溶液的离心管内,混匀,以离心半径7.5cm、1000r/min离10min,分离血浆备用。分别取0.1ml实施例2、对比例1的产品和0.1ml上述血浆于离心管中混合,在37℃水浴下预温 1min后加入0.1ml 0.2%的CaCl2溶液,混匀并开始计时,在有白色胶状物产生时停止计时,重复三次取平均值。实施例2平均体外凝血时间为243±13秒,对比例1平均体外凝血时间为365±9秒,即添加二氧化氯有助于伤口迅速凝血,对伤口起到更好的保护作用。Take 20.0 ml of mouse venous blood, add it into a centrifuge tube containing 2.0 ml of 3.5% sodium citrate solution, mix well, and separate the plasma for 10 min with a centrifugal radius of 7.5 cm and 1000 r/min. Take 0.1ml of the products of Example 2 and Comparative Example 1 and 0.1ml of the above plasma and mix them in a centrifuge tube. After pre-warming in a 37°C water bath for 1min, add 0.1ml of 0.2% CaCl 2 solution, mix well and start timing. Stop timing when white gums appear, and repeat three times to get the average value. The average in vitro coagulation time of Example 2 was 243±13 seconds, and the average in vitro coagulation time of Comparative Example 1 was 365±9 seconds, that is, the addition of chlorine dioxide helped the wound to coagulate rapidly and played a better protective effect on the wound.
(8)丙烯酸/N-乙烯基吡咯烷酮互穿网络水凝胶PH敏感性测定:(8) PH sensitivity determination of acrylic acid/N-vinylpyrrolidone interpenetrating network hydrogel:
分别用2mol/L盐酸及2mol/L氢氧化钠配置PH为2-12的系列溶液,分别取相同质量实施例2及对比例2产品,将凝胶放入溶液中浸泡至充分溶胀取出,用滤纸擦去凝胶外表面参与溶液,称取质量计算溶胀率。以PH值为横坐标,溶胀率为纵坐标作图进行对比,如图4。Use 2mol/L hydrochloric acid and 2mol/L sodium hydroxide to configure the series solutions of PH of 2-12 respectively, take the products of Example 2 and Comparative Example 2 of the same quality respectively, put the gel into the solution and soak it until it is fully swollen to take out. The filter paper wiped off the outer surface of the gel to participate in the solution, and the mass was weighed to calculate the swelling rate. Take the pH value as the abscissa and the swelling rate as the ordinate for comparison, as shown in Figure 4.
G1:溶胀前质量/gG 1 : mass before swelling/g
G2:溶胀前质量/gG 2 : mass before swelling/g
观察实施例2及对比例2溶胀率与PH关系图,可以发现实施例2由于使用丙烯酸/N-乙烯基吡咯烷酮互穿网络水凝胶,可在不同PH情况下实现不同溶胀率,从而控制二氧化氯释放量,而对比例2丙烯酸/N-乙烯基吡咯烷酮水凝胶凝胶在不同PH情况下溶胀率基本不变,不能实现PH响应。Observing the relationship between the swelling ratio and pH of Example 2 and Comparative Example 2, it can be found that in Example 2, due to the use of acrylic acid/N-vinylpyrrolidone interpenetrating network hydrogel, different swelling ratios can be achieved under different pH conditions, thereby controlling the two. The amount of chlorine oxide released, while the swelling rate of the acrylic acid/N-vinylpyrrolidone hydrogel gel in Comparative Example 2 was basically unchanged under different pH conditions, and the pH response could not be achieved.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210383861.7A CN114732942B (en) | 2022-04-12 | 2022-04-12 | A kind of chlorine dioxide sustained-release liquid band-aid and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210383861.7A CN114732942B (en) | 2022-04-12 | 2022-04-12 | A kind of chlorine dioxide sustained-release liquid band-aid and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114732942A true CN114732942A (en) | 2022-07-12 |
CN114732942B CN114732942B (en) | 2023-04-21 |
Family
ID=82281249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210383861.7A Active CN114732942B (en) | 2022-04-12 | 2022-04-12 | A kind of chlorine dioxide sustained-release liquid band-aid and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114732942B (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087326A1 (en) * | 2001-04-30 | 2002-11-07 | Allergan, Inc. | Compositions including vitamin-based surfactants ad methods for using same |
US20030235549A1 (en) * | 2001-05-01 | 2003-12-25 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
CN103881026A (en) * | 2014-03-19 | 2014-06-25 | 浙江大学 | Poly(N-vinylpyrrolidone) microgel as well as preparation method and application thereof |
CN106178094A (en) * | 2016-07-21 | 2016-12-07 | 贵州金玖生物技术有限公司 | A kind of liquid adhesive bandage and preparation method thereof |
CN106476380A (en) * | 2016-09-30 | 2017-03-08 | 广西大学 | A kind of preparation technology of slow released ClO 2 antibacterial film |
US20170156335A1 (en) * | 2014-07-01 | 2017-06-08 | Adva Bar-On | Systems and methods for releasing chlorine dioxide |
CN108751385A (en) * | 2018-04-24 | 2018-11-06 | 苏州国科芯感医疗科技有限公司 | Solid chlorine dioxide slow-release material and preparation method thereof |
CN108785739A (en) * | 2018-08-13 | 2018-11-13 | 中国人民解放军南京军区福州总医院 | A kind of full-service fluid adhesive bandage and preparation method thereof |
CN109420197A (en) * | 2017-08-28 | 2019-03-05 | 娄敬 | Antibacterial hydrogel |
CN109620996A (en) * | 2019-01-29 | 2019-04-16 | 青岛中腾生物技术有限公司 | A kind of medical antibacterial dressing |
-
2022
- 2022-04-12 CN CN202210383861.7A patent/CN114732942B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087326A1 (en) * | 2001-04-30 | 2002-11-07 | Allergan, Inc. | Compositions including vitamin-based surfactants ad methods for using same |
US20030235549A1 (en) * | 2001-05-01 | 2003-12-25 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
CN103881026A (en) * | 2014-03-19 | 2014-06-25 | 浙江大学 | Poly(N-vinylpyrrolidone) microgel as well as preparation method and application thereof |
US20170156335A1 (en) * | 2014-07-01 | 2017-06-08 | Adva Bar-On | Systems and methods for releasing chlorine dioxide |
CN106178094A (en) * | 2016-07-21 | 2016-12-07 | 贵州金玖生物技术有限公司 | A kind of liquid adhesive bandage and preparation method thereof |
CN106476380A (en) * | 2016-09-30 | 2017-03-08 | 广西大学 | A kind of preparation technology of slow released ClO 2 antibacterial film |
CN109420197A (en) * | 2017-08-28 | 2019-03-05 | 娄敬 | Antibacterial hydrogel |
WO2019043547A2 (en) * | 2017-08-28 | 2019-03-07 | 娄敬 | Antibacterial hydrogel |
CN108751385A (en) * | 2018-04-24 | 2018-11-06 | 苏州国科芯感医疗科技有限公司 | Solid chlorine dioxide slow-release material and preparation method thereof |
CN108785739A (en) * | 2018-08-13 | 2018-11-13 | 中国人民解放军南京军区福州总医院 | A kind of full-service fluid adhesive bandage and preparation method thereof |
CN109620996A (en) * | 2019-01-29 | 2019-04-16 | 青岛中腾生物技术有限公司 | A kind of medical antibacterial dressing |
Non-Patent Citations (7)
Title |
---|
HUANG LIJIE: "Kinetic model of a carboxymethylcellulose-Agar Hydrogel for long-acting and slow-release of chhorine dioxide with a modification of fick\'s diffusion law" * |
SANG-HYUN PARK: "Development of sustained release formulations of chlorine dioxide gas for inactivation of foodborne pathogens on produce", 《FOOD SCI TECHNOL INT.》 * |
WEIWEI SUN: "Advances in Research on Sustained-Release Chlorine Dioxide Solid Preparations", 《ADVANCES IN GRAPHIC COMMUNICATION, PRINTING AND PACKAGING TECHNOLOGY AND MATERIALS》 * |
王闯: "智能水凝胶的制备研究", 《化工技术与开发》 * |
胡超云: "稳定性二氧化氯缓释凝胶剂的制备与药效研究", 《中国优秀硕士论文全文数据库》 * |
马小燕: "二氧化氯创面处理剂的发展前景" * |
马小燕: "二氧化氯创面处理剂的发展前景", 《应用化工》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114732942B (en) | 2023-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6568519B2 (en) | Medical covering device | |
CN105597146B (en) | Wound healing multi-functional temperature sensitive gel composite dressing and its preparation and application method | |
JP6069394B2 (en) | Pharmaceutical composition | |
CA2786880C (en) | Antimicrobial agents and methods of use | |
CN104257639B (en) | A kind of liniment for Wound treating and preparation method thereof | |
CN102617878A (en) | Preparation method of chitosan-based antibacterial membrane material | |
CN105561288A (en) | Alanyl-glutamine-containing bioadhesive hydrogel and membrane | |
CN108785739A (en) | A kind of full-service fluid adhesive bandage and preparation method thereof | |
An et al. | Chitosan/rutin multifunctional hydrogel with tunable adhesion, anti-inflammatory and antibacterial properties for skin wound healing | |
WO2024012190A1 (en) | Double-layer bionic drug-loaded hydrogel, and preparation and use thereof | |
MXPA04006907A (en) | Preparation for wound healing and prevention of bandage adhesion to the wound. | |
CN104740141B (en) | A kind of antimicrobial spray and preparation method thereof | |
CN110876814A (en) | Liquid band-aid rich in antibacterial peptide and preparation method thereof | |
CN114732942B (en) | A kind of chlorine dioxide sustained-release liquid band-aid and preparation method thereof | |
CN111184906B (en) | A kind of liquid dressing based on PVA and preparation method thereof | |
Cao et al. | A smart band-aid with temperature and reactive oxygen species dual-responsiveness for synergistic mechanical and pharmacological therapy of chronic wounds | |
CN112438964A (en) | Composite antibacterial film spraying agent of lysostaphin and chitosan | |
CN108354951B (en) | Oxygen-enriched gel for promoting wound healing, preparation method and application | |
RU2649790C1 (en) | Antiseptic composition containing unithiol and dimethylsulfoxide, application of such a composition and method of wound treatment with the use of it | |
CN109200326A (en) | Dressing and adhesive bandage for wound healing | |
EP2170081A1 (en) | Antimicrobial compositions | |
CN115671362A (en) | A kind of alginic acid polysaccharide polymer gel film agent and its preparation method and application | |
TWI334877B (en) | Method for preparing degradable wound dressing | |
CN116942696B (en) | Application of ferrous ions in preparation of scald infection treatment medicines and scald nursing products | |
CN109620842A (en) | Crosslinked polyvinylpyrrolidone and the complex compound of iodine and the preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |